MedTrace Logo

Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)

NCT00898677 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1268

Last updated 2022-02-03

Study results available
· View outcomes & findings →

Summary

A study to compare rizatriptan 10 mg verse sumatriptan 100 mg in the treatment of migraine attacks and duration of relief provided. This study will also provide additional efficacy data on rizatriptan 5 mg and 10 mg for the treatment of migraine.

Conditions

  • Migraine Headache

Interventions

DRUG

rizatriptan benzoate

single dose administration of 5mg rizatriptan (by Mouth) p.o.

DRUG

rizatriptan benzoate

single dose administration of 10 mg rizatriptan p.o.

DRUG

Comparator: sumatriptan

single dose administration of sumatriptan 100 p.o.

DRUG

Comparator: Placebo

placebo to rizatriptan

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-09-30
Primary Completion
1996-05-31
Completion
1996-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00898677 on ClinicalTrials.gov